Cantor Fitzgerald Reaffirms Overweight Rating for Anteris Technologies Global (NASDAQ:AVR)

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald’s target price points to a potential upside of 132.56% from the company’s previous close.

A number of other brokerages have also weighed in on AVR. Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a research report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $14.00.

Anteris Technologies Global Price Performance

AVR stock opened at $6.45 on Wednesday. Anteris Technologies Global has a 1-year low of $3.30 and a 1-year high of $11.06. The company has a market capitalization of $628.62 million, a price-to-earnings ratio of -3.31 and a beta of 1.87. The business has a 50 day simple moving average of $8.32 and a two-hundred day simple moving average of $8.05.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The company had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period last year, the business earned ($0.58) earnings per share. Sell-side analysts anticipate that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insider Activity at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd purchased 272,695 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was bought at an average cost of $7.18 per share, with a total value of $1,957,950.10. Following the completion of the purchase, the insider owned 6,358,271 shares in the company, valued at approximately $45,652,385.78. This represents a 4.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders bought 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. Corporate insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Anteris Technologies Global during the second quarter valued at $56,846,000. ADAR1 Capital Management LLC grew its stake in shares of Anteris Technologies Global by 205.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock worth $21,030,000 after buying an additional 2,550,355 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after buying an additional 1,750,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Anteris Technologies Global in the 2nd quarter worth $33,325,850. Finally, Affinity Asset Advisors LLC increased its holdings in shares of Anteris Technologies Global by 87.5% in the 1st quarter. Affinity Asset Advisors LLC now owns 912,397 shares of the company’s stock worth $5,064,000 after buying an additional 425,713 shares during the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.